Citadel Advisors’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Citadel Advisors’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.14M	Sell	13,126 -8,265	-39%	-$723K	﹤0.01%	7370
2025 Q4	$1.81M	Buy	21,391 +14,557	+213%	+$1.16M	﹤0.01%	6128
2025 Q3	$496K	Sell	6,834 -31,487	-82%	-$2.17M	﹤0.01%	9163
2025 Q2	$2.51M	Buy	38,321 +15,921	+71%	+$1.04M	﹤0.01%	5294
2025 Q1	$1.58M	Buy	22,400 +3,692	+20%	+$257K	﹤0.01%	5990
2024 Q4	$1.23M	Buy	18,708 +13,592	+266%	+$935K	﹤0.01%	6597
2024 Q3	$361K	Sell	5,116 -18,789	-79%	-$1.31M	﹤0.01%	8924
2024 Q2	$1.59M	Sell	23,905 -19,484	-45%	-$1.28M	﹤0.01%	5744
2024 Q1	$2.95M	Sell	43,389 -45,732	-51%	-$3.02M	﹤0.01%	4821
2023 Q4	$5.51M	Buy	89,121 +67,095	+305%	+$3.94M	﹤0.01%	3643
2023 Q3	$1.3M	Buy	+22,026	New	+$1.35M	﹤0.01%	6044
2023 Q2	–	Sell	-21,984	Closed	-$1.28M	–	14759
2023 Q1	$1.28M	Sell	21,984 -61,530	-74%	-$3.71M	﹤0.01%	6260
2022 Q4	$5.18M	Buy	83,514 +29,676	+55%	+$1.79M	﹤0.01%	3807
2022 Q3	$3.04M	Buy	+53,838	New	+$3.32M	﹤0.01%	4783
2022 Q2	–	Sell	-28,866	Closed	-$1.87M	–	13432
2022 Q1	$1.87M	Buy	+28,866	New	+$1.83M	﹤0.01%	6238
2021 Q4	–	Sell	-124,905	Closed	-$7.63M	–	14241
2021 Q3	$7.63M	Buy	124,905 +4,188	+3%	+$266K	﹤0.01%	3533
2021 Q2	$7.47M	Buy	120,717 +115,575	+2,248%	+$7.03M	﹤0.01%	3616
2021 Q1	$304K	Sell	5,142 -43,302	-89%	-$2.61M	﹤0.01%	10827
2020 Q4	$2.9M	Buy	48,444 +4,929	+11%	+$281K	﹤0.01%	4639
2020 Q3	$2.37M	Sell	43,515 -95,139	-69%	-$5.13M	﹤0.01%	4417
2020 Q2	$7.11M	Buy	138,654 +63,606	+85%	+$3.2M	﹤0.01%	2615
2020 Q1	$3.37M	Sell	75,048 -48,537	-39%	-$2.45M	﹤0.01%	3284
2019 Q4	$6.6M	Buy	123,585 +86,088	+230%	+$4.24M	﹤0.01%	2727
2019 Q3	$1.75M	Buy	37,497 +2,382	+7%	+$114K	﹤0.01%	4699
2019 Q2	$1.76M	Sell	35,115 -86,736	-71%	-$4.29M	﹤0.01%	4728
2019 Q1	$6.25M	Buy	121,851 +116,673	+2,253%	+$5.81M	﹤0.01%	2677
2018 Q4	$243K	Sell	5,178 -47,589	-90%	-$2.44M	﹤0.01%	7592
2018 Q3	$2.95M	Buy	+52,767	New	+$2.88M	﹤0.01%	3761
2018 Q2	–	Sell	-20,109	Closed	-$989K	–	9025
2018 Q1	$989K	Sell	20,109 -95,598	-83%	-$4.91M	﹤0.01%	4824
2017 Q4	$5.95M	Sell	115,707 -14,574	-11%	-$749K	﹤0.01%	2275
2017 Q3	$6.79M	Buy	130,281 +119,325	+1,089%	+$6.13M	0.01%	1967
2017 Q2	$567K	Sell	10,956 -112,803	-91%	-$5.7M	﹤0.01%	4937
2017 Q1	$6.23M	Buy	123,759 +5,529	+5%	+$274K	0.01%	1832
2016 Q4	$5.57M	Buy	118,230 +109,653	+1,278%	+$5.2M	0.01%	1889
2016 Q3	$427K	Sell	8,577 -46,473	-84%	-$2.36M	﹤0.01%	5104
2016 Q2	$2.65M	Buy	55,050 +41,571	+308%	+$1.98M	﹤0.01%	2437
2016 Q1	$615K	Sell	13,479 -9,384	-41%	-$439K	﹤0.01%	4116
2015 Q4	$1.23M	Sell	22,863 -37,074	-62%	-$1.95M	﹤0.01%	3326
2015 Q3	$2.96M	Sell	59,937 -13,941	-19%	-$799K	﹤0.01%	2485
2015 Q2	$4.3M	Buy	+73,878	New	+$4.32M	﹤0.01%	2200
2015 Q1	–	Sell	-86,217	Closed	-$4.35M	–	8666
2014 Q4	$4.35M	Buy	+86,217	New	+$4.2M	﹤0.01%	2109
2014 Q2	–	Sell	-14,202	Closed	-$600K	–	8104
2014 Q1	$600K	Buy	+14,202	New	+$595K	﹤0.01%	4089

Other funds holding IHE

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $8.07B AUM 24.97% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return

MSCM

McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

ACM

Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Citadel Advisors's IHE Position: Q1 2026 in Review

Citadel Advisors reduced its iShares US Pharmaceuticals ETF (IHE) stake by 39% in Q1 2026, selling an estimated $723K and leaving 13,126 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #7370.

Citadel Advisors first reported a position in IHE in Q1 2014 and has held it in 42 quarters since. The position peaked at $7.63M in Q3 2021. 194 funds tracked by Wall St. Rank hold IHE as of Q1 2026.

Citadel Advisors held 13,126 shares of iShares US Pharmaceuticals ETF worth $1.14M as of Q1 2026.
Citadel Advisors sold 8,265 iShares US Pharmaceuticals ETF shares in Q1 2026, an estimated $723K.
iShares US Pharmaceuticals ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7370 holding.
Citadel Advisors first reported a position in iShares US Pharmaceuticals ETF in Q1 2014 and has held it in 42 quarters since.
Citadel Advisors's iShares US Pharmaceuticals ETF position peaked at $7.63M in Q3 2021.
194 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.